-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%

Reuters · 01/06/2023 08:23
BRIEF-Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%

- Ligand Pharmaceuticals Inc LGND.O:

  • LIGAND’S PARTNER NOVAN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR BERDAZIMER GEL, 10.3% (SB206) FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM

  • LIGAND PHARMACEUTICALS INC - POTENTIAL FDA APPROVAL ANTICIPATED IN Q1 OF 2024, ASSUMING FDA FILING ACCEPTANCE AND STANDARD REVIEW TIMELINES

Source text for Eikon: ID:

Further company coverage: LGND.O


((Reuters.Briefs@thomsonreuters.com;))